Year: 2025

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations,...

rYojbaba Expands Core Consulting and Health Services Business Internationally Through Partnerships with Koyamada International Foundation and Guardian Girls International

FUKUOKA, Japan, Oct. 17, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor...

At 2025 STAT Summit, Guests including Joe Kennedy III, AMA President, Former NIH Leaders, Explore CRISPR, Pharma, Public Health, and More

BOSTON, Oct. 17, 2025 /PRNewswire/ -- The seventh annual STAT Summit kicked off Wednesday in Boston, bringing together a carefully curated...

Nabsys Presents Data Detailing OhmX™ Platform’s Unique Advantages of Genome Mapping at American Society of Human Genetics (ASHG) 2025 Annual Meeting

Electronic genome mapping (EGM) detects and validates structural variants in cancer genomes with improved accuracy over existing platforms, including optical...

error: Content is protected !!